{"entity":{"id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","aka":[],"tldr":"A phase 2 trial of DZD8586 in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.","summary":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) is a phase 2 interventional study registered as NCT06539182 by Dizal Pharmaceuticals, with 155 participants planned, started 2024-04-29 and due to reach its primary completion in 2027-09. Interventions recorded: DZD8586.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06539182","url":"https://clinicaltrials.gov/study/NCT06539182"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["dzd8586"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06539182","phase":"2","setting":"A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"Dizal Pharmaceuticals","enrolled":155,"outcomes":[]},"route":"/trials/nct06539182/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}]}}